Ficlatuzumab is under clinical development by AVEO Pharmaceuticals and currently in Phase III for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase III drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ficlatuzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ficlatuzumab overview
Ficlatuzumab (AV-299, SCH 900105) is under development for the treatment of advanced or recurrent/metastatic head and neck squamous cell carcinoma, oropharyngeal cancer, nasopharyngeal cancer, metastatic pancreatic ductal adenocarcinoma and metastatic adenocarcinoma of the pancreas. It is a functional anti-hepatocyte growth factor (HGF) monoclonal antibody. It is administered intravenously through infusion. Through the use of human response platform, the HGF/c-Met pathway identified as a significant driver of tumor growth.
It was also under development for the treatment of non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, undifferentiated carcinoma, or poorly differentiated carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx, relapsed or refractory acute myeloid leukemia, advanced metastatic colorectal, head and neck squamous cell carcinoma, breast, gastric/esophageal cancer with liver metastases and advanced solid tumors such as non-small cell lung cancer.
AVEO Pharmaceuticals overview
AVEO Pharmaceuticals (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. AVEO is headquartered in Boston, Massachusetts, the US.
For a complete picture of Ficlatuzumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
